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OBJECTIVE: To evaluate hematological, cytogenetic and molecular responses as well as the overall, progression-
free and event-free survivals of chronic myeloid leukemia patients treated with a third tyrosine kinase inhibitor
after failing to respond to imatinib and nilotinib/dasatinib.
METHODS: Bone marrow karyotyping and real-time quantitative polymerase chain reaction were performed at
baseline and at 3, 6, 12 and 18 months after the initiation of treatment with a third tyrosine kinase inhibitor.
Hematologic, cytogenetic and molecular responses were defined according to the European LeukemiaNet
recommendations. BCR-ABL1 mutations were analyzed by Sanger sequencing.
RESULTS: We evaluated 25 chronic myeloid leukemia patients who had been previously treated with imatinib and a
second tyrosine kinase inhibitor. Nine patients were switched to dasatinib, and 16 patients were switched to nilotinib
as a third-line therapy. Of the chronic phase patients (n=18), 89% achieved a complete hematologic response, 13%
achieved a complete cytogenetic response and 24% achieved a major molecular response. The following BCR-ABL1
mutations were detected in 6/14 (43%) chronic phase patients: E255V, Y253H, M244V, F317L (2) and F359V. M351T
mutation was found in one patient in the accelerated phase of the disease. The five-year overall, progression-free and
event-free survivals were 86, 54 and 22% (po0.0001), respectively, for chronic phase patients and 66%, 66% and 0%
(po0.0001), respectively, for accelerated phase patients. All blast crisis patients died within 6 months of treatment.
Fifty-six percent of the chronic phase patients lost their hematologic response within a median of 23 months.
CONCLUSIONS: Although the responses achieved by the third tyrosine kinase inhibitor were not sustainable, a
third tyrosine kinase inhibitor may be an option for improving patient status until a donor becomes available
for transplant. Because the long-term outcome for these patients is poor, the development of new therapies for
resistant chronic myeloid leukemia patients is necessary.
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’ INTRODUCTION
Second-generation tyrosine kinase inhibitors (TKIs),
such as nilotinib and dasatinib, are effective therapeutic
options for chronic myeloid leukemia (CML) patients who
have failed to respond to imatinib as a first-line therapy.
Indeed, approximately 50% of chronic phase (CP) patients
achieve a complete cytogenetic response (CCyR) when
treated with second-generation TKIs (1,2). Nevertheless,
approximately 52% of patients must discontinue second-
line TKI therapy, most often due to resistance or intoler-
ance (3).
Allogeneic transplantation is the treatment of choice for
patients who fail to respond to at least one second-generation
TKI (2nd TKI). However, transplantation is not feasible for
many older patients, for patients with poor performance
status and for patients who do not have an available donor.DOI: 10.6061/clinics/2015(08)04
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These patients may be switched to a different TKI that was
not used previously or switched to other drugs, such as
interferon (INF) or hydroxyurea (HU) (4). Patients treated
with a 3rd TKI should be closely monitored because novel
mutations can occur with sequential TKI therapy, increasing
the risk of resistance (5,6).
In Brazil, fewer treatment options are available for
resistant cases as other TKIs, such as bosutinib and
ponatinib, are not available. In this study, we present our
experience with CML patients treated with dasatinib or
nilotinib as a third-line (3rd TKI) therapy and emphasize the
importance of developing other therapeutic options for these
patients.
’ PATIENTS AND METHODS
Between July 2008 and December 2014, 213 CML patients
were treated at the Hematology and Hemotherapy Center at
the University of Campinas according to the 2006 and 2009
European LeukemiaNet recommendations (7,8). The first-
line treatment for CML in Brazil is imatinib. The second-line
TKI is chosen based on clinical factors, BCR-ABL1 mutation
status and drug availability. Dasatinib was approved in 2008
and nilotinib was approved in 2009 in Brazil; before 2008,
these drugs were available only through clinical trials. A
total of 25 consecutive adult CML patients, 18 (72%) of
whom were in the CP stage, 3 (12%) of whom were in the AP
stage and 4 (16%) of whom were in the BC stage, who were
resistant (n=23) or intolerant (n=2) to two prior TKIs and
were switched to a 3rd TKI, were included in our analysis.
Most of the patients were treated at our center since their
initial diagnosis; however, three patients were referred from
other treatment centers at the time of initiation of the 2nd TKI
treatment and were followed at our center after discontinua-
tion of the 2nd TKI. Patients were treated with 100-140 mg
dasatinib daily (n=9) (after failure with imatinib and
nilotinib) or 400-800 mg nilotinib daily (n=16) (after failure
with imatinib and dasatinib). Doses were adjusted according
to tolerance. Hematologic, cytogenetic and molecular
responses as well as the CML phases were defined according
to the European LeukemiaNet recommendations (8,9). Bone
marrow karyotyping was performed using the Giemsa-
Trypsin-Wright stain banding technique at baseline and at
3, 6, 12 and 18 months after the initiation of therapy with the
3rd TKI. Twenty metaphase cells were analyzed for each
sample (10).
Detection of BCR-ABL1 transcripts
BCR-ABL1 transcripts were measured in the peripheral
blood by real-time quantitative polymerase chain reaction
(RQ-PCR) at baseline and then every 3 months using
procedures described elsewhere with some modifications
(11). First, cDNAwas amplified using the ABI 7300 sequence
detection system (Applied Biosystems) and TAQMAN
Universal Master Mix in a final reaction volume of 25 mL
according to the instructions recommended by the manu-
facturer. ABL1 was used for normalization. BCR-ABL1
transcripts were measured in duplicate. The copy numbers
were calculated by comparison with a standard curve
generated from serial dilutions (4-6 dilutions) of a linearized
plasmid containing a BCR-ABL1 insert, which has been
described previously (12). The results were reported as BCR-
ABL1/ABL1 ratio (%) after conversion to the international
scale (IS). Major molecular response (MMR) was defined as a
transcript level p0.1% (IS).
Detection of BCR-ABL1 kinase domain mutations
Mutations were detected by direct sequencing of DNA
from peripheral blood samples collected from TKI-resistant
CML patients who failed or displayed a sub-optimal
response to IM or a 2nd TKI, according to methods that
were described previously (13,14). Briefly, total RNA was
transcribed to cDNA and then was amplified using Taq
platinum high fidelity and primers; the forward primer
annealed to BCR exon 2, and the reverse primer annealed to
ABL exon 10. The PCR product was amplified in a semi-
nested reaction, resulting in a 863-base pair fragment that
was sequenced in both directions. The sample nucleotide
sequences were compared to the GenBank accession
no. X16416.
Statistical methods
Probabilities of overall survival (OS), progression-free
survival (PFS) and event-free survival (EFS) were calculated
using the Kaplan-Meier method. OS was calculated at the
initiation of therapy with the 3rd TKI until the final follow-up
or death for any reason. PFS was defined as survival without
transformation to the accelerated or blastic phase after
starting the 3rd TKI and was judged based on an event of
progression or death. EFS was defined as loss of complete
hematological response (CHR), CCyR, MMR, progression to
advanced phases, death or 3rd TKI discontinuation for any
reason (toxicity, resistance, transplant or patient lost to
follow-up). Po0.05 was considered statistically significant.
The cut-off for the data analysis was March 2015.
Ethics
The study protocol was approved and was conducted in
accordance with the ethical standards of the local Research
Ethics Committee on human experimentation and the
Helsinki Declaration of 1975, which was revised in 1983.
Patients provided written informed consent for their
participation.
’ RESULTS
Clinical and laboratory characteristics of the 25 CML
patients at the time of diagnosis and before the initiation of
the 3rd TKI are presented in Tables 1 and 2, respectively.
Chronic-phase CML patients (CP-CML) (n=18) were
analyzed separately. Thirteen CP-CML patients were resis-
tant to imatinib (72%), and 5 were intolerant to imatinib
(28%). Five patients were treated with dasatinib (28%), and
13 patients were treated with nilotinib (72%). Sixteen patients
(89%) were resistant to the 2nd TKI, and 2 patients (11%) were
intolerant to the 2nd TKI. The resistant patients never
achieved a previous CCyR with imatinib or with the 2nd
TKI. The median follow-up duration was 52 (7-75) months,
and 16/18 patients (89%) achieved or maintained a complete
hematologic response during this period. Of 15 patients who
were subjected to cytogenetic analysis, 2 (13%) achieved
CCyR. Of 17 CP-CML patients with available molecular
analysis data, 4 (24%) achieved a major molecular response
(MMR), and 2 achieved a complete molecular response
(CMR). For CP-CML patients, the frequencies of the transcript
levels at baseline and at 3 and 6 months after the initiation of
the 3rd TKI are shown in Table 3.
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Mutation analysis
BCR-ABL1 mutations were evaluated in 14 of 18 CP-CML
patients, and mutations were detected in 6/14 patients
(43%). One patient in the AP stage presented with the
mutation M351T. The mutation F317L was found in 3
patients before the initiation of the 3rd TKI (during second-
line dasatinib therapy), and the mutation F359V was found
in one patient, who displayed imatinib resistance, before the
initiation of dasatinib as a 2nd-line therapy. Five mutations
were found during 3rd-line TKI therapy: E255V (dasatinib),
Y253H (dasatinib), M244V (dasatinib), and F317L (nilotinib).
The patient with the F359V mutation presented with a long
history of disease and had been treated previously for
12 years at another center with busulfan and hydrea before
imatinib treatment. The F359V mutation was detected for the
first time when a patient developed imatinib resistance, but
at the time there were no 2nd-line inhibitors available in
Brazil. The patient underwent hematopoietic stem cell
transplantation (HSCT) and relapsed one and a half years
later with persistence of the F359V mutation. The patient was
treated with dasatinib and achieved CHR but never achieved
a major cytogenetic response. After 4 years of dasatinib
treatment, the patient progressed to the AP stage. At this
time, a new mutation analysis was performed, which
revealed no evidence of the F359V mutation, but a new
mutation, F317L, was identified. The patient was treated
with nilotinib and achieved CHR but relapsed after
5 months; at the time of relapse, the patient maintained the
F317L mutation. A second HSCT was performed, which
resulted in the achievement of a complete molecular response,
but the patient died due to graft-versus-host disease.
Survival analysis
One patient in the CP stage died during 3rd TKI therapy.
CP-CML patients had 5-year OS, PFS and EFS values of 86,
54 and 22% (po0.0001), respectively, whereas AP-CML
patients had 5-year OS, PFS and EFS values of 66, 66 and
0%, respectively (po0.0001). BC-CML patients showed no
response in the first year after treatment (Figures 1, 2 and 3).
Long-term outcome
During treatment, 9/16 (56%) CP-CML patients lost CHR
within a median of 23 (3-37) months. Two patients lost CCyR
after 12 and 13 months. One patient lost MMR after
7 months. Six (34%) patients are currently taking their 3rd
TKI, although 3 of these patients lost their response (1 MMR,
1 CCyR and 1 CHR). Three CP-CML patients (17%)
progressed to the BC (blast crisis) stage, and 2 CP-CML
patients subsequently died. Discontinuation of the 3rd TKI
occurred in 16 (89%) cases due to resistance (8); intolerance
(3); loss to follow-up (3); and death (2) during the treatment.
Three AP-CML patients reached CHR, but one of these
patients lost their response. Only one patient achieved CCyR
and MMR, but those responses were lost. One patient
discontinued treatment due to intolerance in the 4th month.
Table 1 - Characteristics of chronic myeloid leukemia patients at diagnosis (n=25).
Variables n. %
Median age (range) years 45 (14-72)
Gender: male 13 52
Sokal risk group
Low 5 20
Intermediate 1 4
High 9 36
Missing 10 40
Additional chromosomal abnormalities* 01/09 11.1
Splenomegaly 11/16 68.7
Spleen size 410 cm below the costal margin 06/11 54.4
White cell count x 109/L (median, range) 137.10 (17.1 – 494.4)
Platelet count x 109/L (median, range) 352.0 (141.0 - 2,901.0)
Hemoglobin, g/L (median, range) 10.2 (5.1 – 13.7)
Blasts PB, % (median, range) 3.5 (0 - 17)
Basophils PB, % (median, range) 4 (0 - 34)
* 47, XX, t (9;22) (q34;q11), +der(22)
Table 2 - Clinical and laboratory characteristics of chronic
myeloid leukemia patients at the initiation of the 3rd tyrosine
kinase inhibitor (n=25).
Variables n= 25
Median age (range) years 56 (22-75)
Median time of imatinib therapy (range) months 30 (1-66)
Achievement of CCyR with imatinib treatment n (%) 3 (12%)
Interval diagnosis – 3rd TKI (range) months 98 (12-404)
Treated with dasatinib 100-140 mg once daily n (%) 16 (64%)
Treated with nilotinib 400 mg BID n (%) 09 (36%)
Disease status before 3rd TKI n (%)
CP 18 (72%)
AP 03 (12%)
BC 04 (16%)
Table 3 - Molecular responses of chronic phase-chronic myeloid
leukemia patients treated with a 3rd tyrosine kinase inhibitor.
Time RQ-PCR (IS)% N %
Baseline 410 11/18 61
1 – 10 04/18 22
0.1 – 1o 03/18 17
p0.1 0 0
3 months 410 09/12 75
1 – 10 02/12 17
0.1 – 1o 0 0
p0.1 1/12 08
6 months 410 04/08 50
1 – 10 01/08 12.5
0.1 – 1o 01/08 12.5
p0.1 02/08 25
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Figure 1 - Kaplan-Meier survival analysis. Five-year OS of chronic myeloid leukemia patients treated with a 3rd tyrosine kinase inhibitor
according to disease phase.
Figure 2 - Kaplan-Meier survival analysis. Five-year PFS of chronic myeloid leukemia patients treated with a 3rd tyrosine kinase inhibitor
according to disease phase.
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Four BC-CML patients did not reach hematological or
cytogenetic responses and died within four months of the
initiation of the 3rd TKI.
Regarding other treatments after discontinuation of the 3rd
TKI, 14 patients were treated with the following drugs:
hydrea (8), hydrea followed by HSCT (2), hydrea followed
by low dose ARA-C and imatinib (1), interferon followed by
hydrea (1), imatinib (1), and conventional chemotherapy
followed by hydrea (1).
’ DISCUSSION
Our data show that only 22% of patients in the CP stage
showed long-term benefits from the administration of a 3rd
TKI after imatinib and a 2nd TKI failure. We found that 89%
of our patients in the CP stage achieved CHR, 13% achieved
CCyR, and 24% achieved MMR; however, 50% of those
patients lost CHR within a median of 23 months. All patients
with CCyR lost their response after 12 months, and 25% of
patients lost MMR after 7 months.
Our results are in agreement with prior reports. Quintas-
Cardama et al. (15) performed a study on 23 CML patients
treated with dasatinib after imatinib and nilotinib failure and
found that 43% of these patients achieved CHR and 30%
achieved a cytogenetic response. Giles et al. (16), performed a
study analyzing 60 patients treated with nilotinib after
imatinib and dasatinib failure and found that 70% of CP-
CML patients achieved CHR and 43% of CP-CML patients
achieved a major cytogenetic response (MCyR). The authors
also found that after 18 months, 59% of CP-CML patients
were progression-free, and their estimated survival was 86%.
Regarding molecular responses, most of our patients had
BCR-ABL1 transcript levels 410% at 3 months (75%) and
41% at 6 months (62.5%). The achievement of early
responses to first- and second-line therapies, such as BCR-
ABL1 transcript levels o10% at 3 months and o1% at
6 months, has been associated with long-term cytogenetic
and molecular responses and better clinical outcomes
(3,17–22). Only one patient in the CP stage achieved the
optimal response criteria within 3 months and 6 months,
respectively.
In our study, the EFS was 44% at 27 months for CP-CML
patients, which is similar to the findings reported by Ibrahim
et al. (23), where 26 CP-CML patients who failed to respond
to two prior TKIs had 45.7% EFS at 30 months after the
initiation of a 3rd TKI. These results show that although
patients can achieve hematological and cytogenetic
responses with a 3rd TKI, those responses are not sustainable.
Similar observations were made by Garg et al.(24). The
authors evaluated 48 CML patients, 25 of whom were in
the CP stage, treated sequentially with three TKIs. Three
patients in the CP stage and one in the AP stage achieved
CCyR; the median duration of the response was 16.3 months.
The median failure-free survival was 20 months for patients
in the CP stage, 5 months for patients in the AP stage, and
3 months for patients in the BP stage.
Patients treated with sequential TKIs also have a higher
risk of developing resistance and novel mutations (5,6). In
fact, 76% of our patients discontinued the 3rd TKI, and 42%
of those discontinuations were due to resistance. We
found 5 BCR-ABL1 mutations in 14 CP patients during the
3rd TKI therapy. One patient harbored a F359V mutation
and responded to dasatinib, however, another mutation
Figure 3 - Kaplan-Meier survival analysis. Five-year event-free survival of chronic myeloid leukemia patients treated with a 3rd tyrosine
kinase inhibitor according to disease phase.
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was selected in this patient when the disease progressed
(F317L).
Although the responses to 3rd-line TKI therapy are not
sustainable, 3rd-line TKIs may be an alternative for patients
with CML who failed to respond to imatinib and a second
generation TKI and are not eligible for HSCT (4). A 3rd-line
TKI can improve the patient’s condition until an alternative
transplant donor is available. Nevertheless, because the long-
term outcome of these patients is poor, it is important to
emphasize the importance of developing new therapies for
CML resistant patients.
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